Top Artificial Intelligence-Based Healthcare Mobile Apps and Their Use Cases

Endocrinology and Metabolic Disorders

Precigen’s PRGN-3006; Yescarta Approved a...

FDA Approves Yescarta as a First CAR T-cell Therapy for Initial Treatment of R/R Large B-cell Lymphoma Until now, existing CAR-T therapies have been reserved for patients with blood cancer who have...

Apr 05, 2022

MedTech News for Ypsomed Fresenius Kabi Sientra Synchron HLT
Ypsomed-CamDiab’s Collaboration; Vela Diagnostics’s NGS-Based Pan-Cancer Panels; Fresenius’s SMOFlipid Lipid Injectable Emulsion; Sientra Gained Regulatory Nod to Market Breast Implants; Synchron’s Endovascular BCI Stentrode Device; HLT’s TAVR Clinical Studies

Ypsomed Collaborated with CamDiab for Smartphone-based Automated Insulin Delivery On March 22, 2022, Ypsomed, a leading manufacturer of injection and infusion systems for self-medication partnered with CamDiab Ltd, developer of CamAPS FX, an app for the management of glucose levels via insulin pumps using an ada...

Find More
Top Drugs Losing Patent Protection in 2022
Analyzing the Most Promising Drugs That Will Lose Patent in the US & EU in 2022

Patent protection and expiration is one of the hot topics in the healthcare industry. Patent protection results in high sales and profits for the initial developers and innovators of the drugs, and as per various estimates, the gross profit margins for the Patent protected drugs exceed 90% in some cases. However, t...

Find More
Pharma News and Updates for Sanofi ViiV Argenx Novartis UCB Kyowa
Sanofi’s Rare Disease Drug Xenpozyme’ Approval; FDA Approves Novartis’ Pluvicto; AstraZeneca’s Imfinzi Trial Result; FDA’s Green Signal to Argenx’ Vyvgart; ViiV Healthcare and J&J’s HIV Treatment Cabenuva; UCB’s FINTEPLA Approval; Cullinan’s Update for CLN-081; MEI Pharma & Kyowa’s Zandelisib Approval

Sanofi’s Rare Disease Drug Xenpozyme Wins World’s First Approval in Japan Sanofi’s Xenpozyme, also known as olipudase alfa, the world's first therapy for the rare disease Niemann-Pick type A/B and B, has been approved for the treatment of children and adults with non-CNS manifestations of Acid Sphingomyelinase D...

Find More

More Views & Analysis

Potential of Cannabidiol (CBD) as a Treatment Substance
Can Cannabinoids be an Effective Medicinal Substance?

Cannabidiol (CBD) is one of the 120 cannabinoids present naturally in cannabis plants. After tetrahydrocannabinol (THC), Cannabidiol is the second most prevalently available cannabinoid. Cannabidiol, an important component of medicinal marijuana, is either directly from the hemp plant or synthesized in a laboratory...

Find More

medtech-news-for-motus-evoendo-orthofix-invitae-polyactiva-ra-medical
Motus GI’s Pure-Vu EVS System; EvoEndo’s Single-Use Unsedated TNE System; Orthofix’s OpusTM BA; Invitae’s CE-IVD Cancer Testing Kits; PolyActiva’s PA5108 Ocular Implant; Ra Medical’s DABRA excimer laser system

US FDA grants 510(k) clearance to Motus GI’s Pure-Vu EVS System On February 15, 2022, The Pure-Vu® EVS System received 510(k) clearance from the US Food and Drug Administration, according to Motus GI Holdings, Inc., a medical technology company that provides endoscopy solutions that improve clinical outcomes and...

Find More

What-is-the-Scope-of-Adrenal-Crisis-Therapeutic-Treatment-Market-in-the-Coming-Years
Adrenal Crisis – The Hurdles in Diagnosis and Treatment

Adrenal Crisis refers to overwhelming and life-threatening adrenal insufficiency. The most common signs of Adrenal Crisis are shocking (very low blood pressure with a loss of consciousness), dehydration, and an imbalance of sodium and potassium levels in the body. In some cases, shock is then preceded by several ot...

Find More

pharma-news-for-sandoz-agios-organon-bms-sanofi-bayer-lilly
Sandoz’s Generic Revlimid; Agios’ Pyrukynd; Organon Announces 4Q & Full-year Earnings Report; BMS’ CAR-T Drug Breyanzi; Sanofi & Regeneron’s Dupixent Trial; AZ & Daiichi’s Drug Enhertu; Bayer’s Drug Kerendia; Lilly Releases Mirikizumab Data

Sandoz Launches generic Revlimid in 19 European Countries, Bringing a Flood of Competition to BMS' Megablockbuster Since Bristol Myers Squibb acquired Celgene and its megablockbuster Revlimid, the company has been bracing for the day when the multiple myeloma superstar would face generic competition. Sandoz, a s...

Find More

medtech-news-for-insulet-bd-medtronic-artivion-omnysense
Insulet’s Omnipod 5 Automated Insulin Delivery System; Alivecor’s KardiaMobile Card; BD Board Approved the Spinoff of embecta; Medtronic’s Hugo Surgery Robot; Artivion’s On-X® Mitral Heart Valve PROACT; OmnySense’s Smart Thermometer Clinical Trial

Insulet Received FDA Clearance for its Omnipod® 5 Automated Insulin Delivery System, First Tubeless System with Smartphone Control On January 28, 2022, Insulet Corporation, a market leader in developing tubeless insulin pumps with its product, Omnipod®, received the FDA approval for its Omnipod® 5 Automated Insu...

Find More

pharma-news-for-merck-pfizer-gilead-abbvie-lantern-polpharma
Merck’s Gefapixant; Pfizer’s Somatrogon; Gilead’s Viklury; AbbVie’s Skyrizi; Gilead’s Zydelig Approvals; Lantern’s LP-184; Polpharma to Acquire Advent

Merck’s Chronic Cough Med Gefapixant Receives A Red Flag From the FDA, Requests For More Data On 24th January 2022, Merck & Co. announced FDA rejection for its New Drug Application (NDA) of Gefapixant (experimental drug) for unexplained or chronic cough. FDA asked for additional information on the drug, rela...

Find More

Nonalcoholic steatohepatitis (NASH) affects individuals slowly and progressively. Presently, there e.....

Find More

The Digital Era has officially hit Prime Time. Currently, the potentiality to digitally transform a .....

Find More

Gene Therapy has shown tremendous growth in the past few years. The use of AAV (adeno-associated vir.....

Find More

Gastroesophageal Reflux Disease (GERD, also known as chronic acid reflux) is a digestive disorder in.....

Find More

Digital therapies are evidence-based clinical approaches powered by software applications designed t.....

Find More

HIV-associated lipodystrophy (HAL), is a condition characterized by the redistribution of adipose ti.....

Find More